Abstract
We performed a retrospective analysis of DLBCL with breast involvement to compare the prognosis of primary breast lymphoma (PBL) to secondary breast lymphoma (SBL; especially in limited stage cases). We retrospectively reviewed records of 25 diffuse large B-cell lymphoma (DLBCL) patients with breast involvement who received chemotherapy between January 2000 and August 2012. We compared clinical features and prognosis among patients with PBL (n = 11), limited stage SBL (LSBL; n = 6), and advanced stage SBL (ASBL, n = 8). The PBL group had significantly lesser patients with breast tumours (BTs) > 5 cm than the SBL group (P = 0.02). After a median follow-up of 71.3 months, we observed significantly better 5-year overall survival (OS) in the PBL group (90.0%) than in the LSBL (33.3%, P = 0.01) group, but not for progression-free survival (PFS). Patients with BT > 5 cm had worse OS (P = 0.01) and PFS (P = 0.04) than those with BT ≤ 5 cm. PBL had a better prognosis than SBL among limited stage DLBCL.
Similar content being viewed by others
References
Aviv A, Tadmor T, Polliack A (2013) Primary diffuse large B-cell lymphoma of the breast: looking at pathogenesis, clinical issues and therapeutic options. Ann Oncol 24(9):2236–2244
Cheah CY, Campbell BA, Seymour JF (2014) Primary breast lymphoma. Cancer Treat Rev 40(8):900–908
Tomita N, Yokoyama M, Yamamoto W, Watanabe R, Shimazu Y, Masaki Y et al (2012) Central nervous system event in patients with diffuse large B-cell lymphoma in the rituximab era. Cancer Sci 103(2):245–251
Talwalkar SS, Miranda RN, Valbuena JR, Routbort MJ, Martin AW, Medeiros LJ (2008) Lymphomas involving the breast: a study of 106 cases comparing localized and disseminated neoplasms. Am J Surg Pathol 32(9):1299–1309
Wiseman C, Liao KT (1972) Primary lymphoma of the breast. Cancer 29(6):1705–1712
Ryan G, Martinelli G, Kuper-Hommel M, Tsang R, Pruneri G, Yuen K et al (2008) Primary diffuse large B-cell lymphoma of the breast: prognostic factors and outcomes of a study by the International Extranodal Lymphoma Study Group. Ann Oncol 19(2):233–241
Jia Y, Sun C, Liu Z, Wang W, Zhou X (2018) Primary breast diffuse large B-cell lymphoma: a population-based study from 1975 to 2014. Oncotarget. 9(3):3956–3967
Lin YC, Tsai CH, Wu JS, Huang CS, Kuo SH, Lin CW et al (2009) Clinicopathologic features and treatment outcome of non-Hodgkin lymphoma of the breast—a review of 42 primary and secondary cases in Taiwanese patients. Leuk Lymphoma 50(6):918–924
Kanda Y (2013) Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant 48(3):452–458
Fukuhara S, Watanabe T, Munakata W, Mori M, Maruyama D, Kim SW et al (2011) Bulky disease has an impact on outcomes in primary diffuse large B-cell lymphoma of the breast: a retrospective analysis at a single institution. Eur J Haematol 87(5):434–440
Avilés A, Delgado S, Nambo MJ, Neri N, Murillo E, Cleto S (2005) Primary breast lymphoma: results of a controlled clinical trial. Oncology. 69(3):256–260
Niitsu N, Okamoto M, Nakamine H, Hirano M (2008) Clinicopathologic features and treatment outcome of primary breast diffuse large B-cell lymphoma. Leuk Res 32(12):1837–1841
Ludmir EB, Milgrom SA, Pinnix CC, Gunther JR, Westin J, Oki Y et al (2018) Primary breast diffuse large B-cell lymphoma: treatment strategies and patterns of failure. Leuk Lymphoma 59(12):2896–2903
Hu S, Song Y, Sun X, Su L, Zhang W, Jia J et al (2018) Primary breast diffuse large B-cell lymphoma in the rituximab era: therapeutic strategies and patterns of failure. Cancer Sci 109(12):3943–3952
Acknowledgements
We would like to thank Editage (https://www.editage.jp) for English language editing.
Author information
Authors and Affiliations
Corresponding author
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Takahashi, H., Sakai, R., Sakuma, T. et al. Comparison of Clinical Features Between Primary and Secondary Breast Diffuse Large B Cell Lymphoma: A Yokohama Cooperative Study Group for Hematology Multicenter Retrospective Study. Indian J Hematol Blood Transfus 37, 60–66 (2021). https://doi.org/10.1007/s12288-020-01307-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12288-020-01307-7